TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06306976

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Elective Midline Laparotomy
Description: Patients with midline ventral incisional hernia with a range of hernia morphology who plan to undergo open retromuscular VHR.~Hernia repair:~All study patients will have an open retromuscular repair with/without additional lateral MFR (TAR or EOR at the discretion of the operating surgeon). All repairs beginning with retrorectus dissection to the level of the linea semilunaris.~All patients will have permanent mesh reinforcement of the abdominal wall (large-pore, midweight polypropylene). Fascia will be closed over the mesh with 0 or 2-0 polydioxanone slowly absorbable suture using a small-bite technique and a 4:1 suture length:wound length ratio.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Imaging: Ultrasound
Description: Ultrasound procedure will involve the following steps:~1. For control group 1 and group 2 patients, Images will be taken at two points along the bilateral RA; at the level of the umbilicus and midway between the umbilicus and xiphoid process. Bilateral external oblique (EO), internal oblique (IO), and transversus abdominis (TA) images will be performed at the level of the anterior axillary line midway between the costal margin and iliac crest.
Study: NCT05621460

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 500mL carbonated water
Description: Drink 500mL carbonated water immediately prior to head-up tilt test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 500mL carbonated water
Description: Drink 500mL carbonated water immediately prior to head-up tilt test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 500mL still water
Description: Drink 500mL still water immediately prior to head-up tilt test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 500mL still water
Description: Drink 500mL still water immediately prior to head-up tilt test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 500mL still water
Description: Drink 500mL still water immediately prior to head-up tilt test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 500mL still water
Description: Drink 500mL still water immediately prior to head-up tilt test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 500mL still water
Description: Drink 500mL still water immediately prior to head-up tilt test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 500mL still water
Description: Drink 500mL still water immediately prior to head-up tilt test
Study: NCT05035264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal mask insertion
Description: Laryngeal mask insertion in sniffing position
Study: NCT06306976

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Imaging: Ultrasound
Description: Ultrasound procedure will involve the following steps:~1. For control group 1 and group 2 patients, Images will be taken at two points along the bilateral RA; at the level of the umbilicus and midway between the umbilicus and xiphoid process. Bilateral external oblique (EO), internal oblique (IO), and transversus abdominis (TA) images will be performed at the level of the anterior axillary line midway between the costal margin and iliac crest.

Intervention type: OTHER
Group type: OTHER
Intervention: Tensiometry
Description: For all study patients, an analog spring-tensiometer will be used to assess intraoperative tension required to bring the fascia to the midline for closure. The tensiometer is attached to a clamp attached to the fascia at the midpoint of the hernia defect. Tension required for medialization to the midline will be performed after adhesiolysis (baseline), retrorectus dissetion, incision of the PLIO (if performed), and after completion of TAR or EOR (if performed).~Control group 2 patients will be undergoing first time laparotomy and will have tensiometry performed.
Study: NCT05035264

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal mask insertion
Description: Laryngeal mask insertion in sniffing position

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal mask insertion
Description: Laryngeal mask insertion in sniffing position

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal mask insertion
Description: Laryngeal mask insertion in beyond sniffing position

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal mask insertion
Description: Laryngeal mask insertion in beyond sniffing position

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal mask insertion
Description: Laryngeal mask insertion in beyond sniffing position
Study: NCT06280560

Intervention type: PROCEDURE
Intervention: Controlled Ovarian Stimulation + Luteal Phase Support
Description: Short COS protocol with GnRH antagonist followed by progesterone supplementation. Will be initiated after a negative vaginal ultrasonographic scans to define ovarian quiescence, on days 1 and 2 of the menstrual period. For ovarian stimulation, 150-225 UI /day of FSHrec (GONAL F) will be administered along or in combination with 75 UI/day of HMG (Menopur). From day 6 onwards, HMG/FSHrec will be administered on an individual basis according to the serum E2 levels and transvaginal ovarian ultrasound scans and GnRH antagonist (Orgalutran) 0.25 mg /day is introduced as soon as a follicle of 14 mms diameter has achieved. hCGrec (6500 IU, Ovitrelle) will be administered when 7 or 8 follicles with a maximum diameter of \>17-18 mms will observed. 400 mg of micronized vaginal progesterone will be administered (200 mg twice a day vaginal route), during 5 days. An endometrial biopsy and a blood sample will be obtained 7 days after hCG administration (hCH+7)

Intervention type: PROCEDURE
Intervention: Hormonal Replacement Therapy programmed artificial cycle
Description: 6 mg of oestradiol orally administered starting the first day of the menstrual period, followed by an endometrial scan 10-days later, and when a 7 mms triple line endometrium has seen by vaginal ultrasound scan, 800 mg of micronized vaginal progesterone (400 mg twice a day vaginal route), during five days, will be added to the oestrogen therapy. An endometrial biopsy and a blood sample will be obtained on day 5 of progesterone administration (P+5)

Intervention type: PROCEDURE
Intervention: Natural Cycle (NC)
Description: No hormonal stimulation. From day 6 of the menstrual period, follicular growth will be evaluated. As soon as a follicle reaches 17mm in diameter, ovulation test strips will be provided to assess LH levels in the first morning urine. The participant will report the positive and will be scheduled for sampling seven days later. An endometrial biopsy and a blood sample will be obtained 7 days after LH peak (LH+7)

Intervention type: PROCEDURE
Intervention: Endometrial receptivity reference group
Description: Recruited among women belonging to the oocyte donation program and will follow the procedures described above for the Natural Cycle group. No hormonal stimulation. From day 6 of the menstrual period, follicular growth will be evaluated. As soon as a follicle reaches 17mm in diameter, ovulation test strips will be provided to assess LH levels in the first morning urine. The participant will report the positive and will be scheduled for sampling seven days later. An endometrial biopsy and a blood sample will be obtained 7 days after LH peak (LH+7)
Study: NCT06015295

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-Fluciclovine (Axumin)
Description: Given by Injection

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pet Scan
Description: Scans
Study: NCT06667856

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Asynchronous exercise group
Description: Application of foot core training combined with lower extremity exercises using asynchronous telerehabilitation method.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Synchronous exercise group
Description: Application of foot core training combined with lower extremity exercises using synchronous telerehabilitation method.
Study: NCT04831164

Intervention type: OTHER
Intervention: NA (not an interventional study)
Description: (not an interventional study)

Intervention type: OTHER
Intervention: NA (not an interventional study)
Description: (not an interventional study)
Study: NCT06615271

Intervention type: PROCEDURE
Intervention: Neurosurgery
Description: Patients who have undergone neurosurgery form more than 3 hours.
Study: NCT06615648

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PMT
Description: 7-minute PMT intervention video

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-contact Control
Description: 6-minute alternative video
Study: NCT04918108

Intervention type: BIOLOGICAL
Intervention: inflammatory response
Description: laboratory data (leukocyte, neutrophils, monocyte, lymphocytes, platelet, fibrinogen, D-dimer, neutrophils-lymphocyte ratio, platelet-lymphocyte ratio, lymphocyte-monocyte ratio)
Study: NCT05322980

Intervention type: DIAGNOSTIC_TEST
Intervention: Microcephaly
Description: Those with a z score of birth head circumference \< -2 (primary microcephaly) are classified into the Microcephaly group.
Study: NCT06691971

Intervention type: DEVICE
Intervention: AeviceMD
Description: The AeviceMD device will be placed on the patient to detect the presence of wheeze and perform auscultation.

Intervention type: DEVICE
Intervention: AeviceMD
Description: The AeviceMD device will be placed on the patient to detect the presence of wheeze and perform auscultation.
Study: NCT06696248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol and alverine
Description: On the basis of maintaining unchanged routine hepatoprotective and symptomatic supportive treatments and the original dose of carvedilol, participants will be administered with compound alverine citrate capsules (Le Jian Su; specification: each capsule contains alverine citrate 60 mg and simeticone 300 mg; manufactured by Laboratoires MAYOLY SPINDLER), at a dosage of 180 mg/day (1 capsule orally, 3 times a day), for a continuous period of 24 weeks.
Study: NCT06696157

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRSS intervention for MOUD initiation
Description: All participants of this expanded scope pilot study will be in a single-arm of an uncontrolled trial of PRSS intervention for MOUD initiation for a total of 8 weeks, starting in inpatient substance abuse treatment. This is distinguished from the R34 parent grant which targets MOUD retention and adherence rather than MOUD initiation.
Study: NCT06698029

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VIM Targeting
Description: Targeting with the use of VIMRS-LAT-1.0
Study: NCT06696911

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Core stability Exercises
Description: The exercises have been divided into three difficulty categories based on the level of difficulty.~Level I: When the patients were unable to sit independently, level I core stability therapy was administered. First-level exercises were done in a supine position on a plinth. The workout program mostly included side bridging movements, leg crosses, one-leg curl-ups, and straight and diagonal reaching activities. Patients can move to level once they can sit on a plinth edge unsupported for one minute while flexing their knees and hips to 90 degrees.~Level II: Exercises included straight-arm curl-ups, diagonal-arm curl-ups, and arm curl-ups with the arms crossed. The patient will go to stage three once they can sit on an unstable surface for thirty seconds.~Level III: Using a physio ball, the exercises were done while seated. The exercises performed with the ball consisted push-ups, bird dog, side Bridge, abdominal curl-ups, and bridge movements

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Motor Imagery
Description: The motor imagery program will be performed in three steps. STEP 1 Subjects will be instructed to watch the video provided and recorded by investigator. Two types of videos will be available to watch. One recording normal movements and the other film will contain recording the patient movements. Patient will be asked to watch the video and analyze the differences.~STEP 2 In next step participants will be asked to close the eyes to focus and then to imagine how they are doing task they had previously observed 10 times.~STEP 3 Participants will be than instructed to carry out the task in verbal commands given whenever necessary. During the recall process components of movement deviating from normal will be emphasized. The difficulty level of activities and the analysis of movement components will be increased gradually according to the patient's capacity.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Motor Imagery
Description: The motor imagery program will be performed in three steps. STEP 1 Subjects will be instructed to watch the video provided and recorded by investigator. Two types of videos will be available to watch. One recording normal movements and the other film will contain recording the patient movements. Patient will be asked to watch the video and analyze the differences.~STEP 2 In next step participants will be asked to close the eyes to focus and then to imagine how they are doing task they had previously observed 10 times.~STEP 3 Participants will be than instructed to carry out the task in verbal commands given whenever necessary. During the recall process components of movement deviating from normal will be emphasized. The difficulty level of activities and the analysis of movement components will be increased gradually according to the patient's capacity.
Study: NCT06696573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prophylactic NSAID Administration
Description: Participants in this arm will receive a prophylactic dose of a non-steroidal anti-inflammatory drug (NSAID) prior to the onset of pain during medical abortion procedures for pregnancies between 13 and 22 weeks. The intervention aims to reduce pain intensity throughout the process. The NSAID administration involves a specific dosage and schedule, adhering to safety guidelines and monitored for potential side effects.
Study: NCT05281653

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise Training
Description: Progressive neuromuscular exercise training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine training sessions
Description: Routine training sessions
Study: NCT06696573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: On-Demand NSAID Administration
Description: Participants in this group will receive a non-steroidal anti-inflammatory drug (NSAID), such as Ibuprofen, in oral tablet form at a dose of 400 mg. The drug will be administered as needed when participants report experiencing pain during the medical abortion process for pregnancies between 13 and 22 weeks. The goal of this intervention is to provide pain relief in response to individual needs, with administration and dosage adjusted as clinically indicated. Monitoring will occur to assess the efficacy, safety, and patient response to the on-demand approach.
Study: NCT06698224

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal cord transcutaneous stimulation
Description: Physical therapy combined with spinal cord transcutaneous stimulation will increase activity in the paralyzed or weak arm and hand muscles in individuals with spinal cord injury. Transcutaneous spinal cord stimulation is a non-invasive stimulation strategy and are known to facilitate recovery of lost function post spinal cord injury.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paired spinal cord and peripheral nerve stimulation
Description: Physical therapy combined with paired spinal cord-peripheral nerve stimulation will increase activity in the paralyzed or weak arm and hand muscles in individuals with spinal cord injury. Transcutaneous spinal cord and peripheral nerve stimulation are both non-invasive stimulation strategy and are known to facilitate recovery of lost function post spinal cord injury.
Study: NCT06698081

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video Multimedia
Description: The second group will be informed of the Standard Informed Consent Form, Verbal Information, and Multimedia. In addition to the standard consent process, we planned to show a 6-minute video multimedia presentation containing information about undescended testis and orchiopexy.
Study: NCT06696755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icalcaprant
Description: Oral Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icalcaprant
Description: Oral Capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Icalcaprant
Description: Oral Capsules
Study: NCT05559892

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DM-CCT
Description: Participants randomized to DM-CCT will receive cash transfers of $500 per month for 6 months, but the cash transfers will be conditional on attending a 60-minute diabetes education/skills training (30 minutes) and stress/coping (30 minutes) session delivered by trained nurses every 2 weeks for 6 months (12 sessions).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DM-UCT
Description: Participants randomized to UCT will receive cash transfers of $500 per month for 6 months, but there will be no conditions attached. Therefore, they will receive cash transfer payments every month. However, to control for content and attention, participants will receive mailed version of the diabetes education/skills training materials every two weeks on the same schedule as the DM-CCT telephone sessions.
Study: NCT04834024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide
Description: The patients confirming to the eligibility criteria will receive MIL62 from cycle 1 to cycle 30 and lenalidomide from cycle 1 to cycle 18, unless either rapid disease progression or unacceptable toxicity was observed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lenalinomide
Description: The patients confirming to the eligibility criteria will receive lenalidomide for 18 cycles, unless either rapid disease progression or unacceptable toxicity was observed.
Study: NCT04833933

Intervention type: OTHER
Intervention: Phone survey about smoking cessation process since intervention in DISCO trial
Description: We will conduct a phone survey at 2 years follow-up with a random sample of smoking patients at inclusion in DISCO trial, to know the evolution of their smoking habits, the quit attempts since the intervention and the modalities of these attempts.

Intervention type: OTHER
Intervention: Phone survey about smoking cessation process since intervention in DISCO trial
Description: We will conduct a phone survey at 2 years follow-up with a random sample of smoking patients at inclusion in DISCO trial, to know the evolution of their smoking habits, the quit attempts since the intervention and the modalities of these attempts.

Intervention type: OTHER
Intervention: Phone survey about smoking cessation process since intervention in DISCO trial
Description: We will conduct a phone survey at 2 years follow-up with a random sample of smoking patients at inclusion in DISCO trial, to know the evolution of their smoking habits, the quit attempts since the intervention and the modalities of these attempts.

Intervention type: OTHER
Intervention: Phone survey about smoking cessation process since intervention in DISCO trial
Description: We will conduct a phone survey at 2 years follow-up with a random sample of smoking patients at inclusion in DISCO trial, to know the evolution of their smoking habits, the quit attempts since the intervention and the modalities of these attempts.
Study: NCT04985110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole
Description: The treatment group will receive Cotrimoxazole Forte 960 mg PO q.d. 4 hours before the biopsy procedure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group will receive placebo q.d. 4 hours before the biopsy procedure.
Study: NCT05356429

Intervention type: OTHER
Intervention: Small molecule LCDM
Description: The cocktail of small molecules includes four chemical components of LCDM were added to GV oocyte culture medium.
Study: NCT05476731

Intervention type: DIAGNOSTIC_TEST
Intervention: culture and antifungal sensitivity and molecular detection
Description: Samples will be cultured on Modified Dixon media for 10 days at temperature between 32-34°C.Molecular detection of malassezia species by Restriction Fragment Length Polymorphism (RFLP) .~Antifungal susceptibility testing of the isolates will be performed using the following antifungals Fluconazole, AmphotericinB and Fluocytosine

Intervention type: DIAGNOSTIC_TEST
Intervention: culture and antifungal sensitivity and molecular detection
Description: Samples will be cultured on Modified Dixon media for 10 days at temperature between 32-34°C.Molecular detection of malassezia species by Restriction Fragment Length Polymorphism (RFLP) .~Antifungal susceptibility testing of the isolates will be performed using the following antifungals Fluconazole, AmphotericinB and Fluocytosine
Study: NCT05067790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nusinersen
Description: Administered as specified in the treatment arm
Study: NCT05890638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium / Levosalbutamol Fixed Dose Combination
Description: New combination test treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipratropium + Levosalbutamol Free Dose Combination
Description: Free combination control treatment
Study: NCT04898309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNR-038, 50 МЕ/ kg
Description: A single intravenous infusion of GNR-038, 50 МЕ/ kg less than 5 hours after the onset of edema.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNR-038, 100 МЕ/ kg
Description: A single intravenous infusion of GNR-038, 100 МЕ/ kg less than 5 hours after the onset of edema.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berinert®, 20 МЕ/ kg
Description: A single intravenous infusion of Berinert®, 20 МЕ/ kg less than 5 hours after the onset of edema.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A single intravenous infusion of Placebo less than 5 hours after the onset of edema.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNR-038. The dose will be selected according to results of stage 1 clinical trial.
Description: A single intravenous infusion of GNR-038 less than 5 hours after the onset of edema.